Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer
Panagiotis A. Konstantinopoulos, Stephen A. Cannistra, Helen Fountzilas et al. · PLoS ONE · 2011
BACKGROUND: Public data integration may help overcome challenges in clinical implementation of microarray profiles. We integrated several ovarian cancer datasets to identify a reproducible predictor of survival. METHODOLOGY/PRINCIPAL FINDINGS: Four microarray datasets from different institutions comprising 265 advanced stage tumors were uniformly reprocessed into a single training dataset, also adjusting for inter-laboratory variation ("batch-effect"). Supervised principal component survival analysis was employed to identify prognostic models. Models were independently validated in a 61-patient cohort using a custom array genechip and a publicly available 229-array dataset. Molecular correspondence of high- and low-risk outcome groups between training and validation datasets was demonstrated using Subclass Mapping. Previously established molecular phenotypes in the 2(nd) validation set were correlated with high and low-risk outcome groups. Functional representational and pathway analysis was used to explore gene networks associated with high and low risk phenotypes. A 19-gene model showed optimal performance in the training set (median OS 31 and 78 months, p < 0.01), 1(st) validation set (median OS 32 months versus not-yet-reached, p = 0.026) and 2(nd) validation set (median OS 43 versus 61 months, p = 0.013) maintaining independent prognostic power in multivariate analysis. There was strong molecular correspondence of the respective high- and low-risk tumors between training and 1(st) validation set. Low and high-risk tumors were enriched for favorable and unfavorable molecular subtypes and pathways, previously defined in the public 2(nd) validation set. CONCLUSIONS/SIGNIFICANCE: Integration of previously generated cancer microarray datasets may lead to robust and widely applicable survival predictors. These predictors are not simply a compilation of prognostic genes but appear to track true molecular phenotypes of good- and poor-outcome.
Cited by 34 works. doi:10.1371/journal.pone.0018202 Open-access PDF
Authors
- Panagiotis A. Konstantinopoulos
- Stephen A. Cannistra
- Helen Fountzilas
- Aedín C. Culhane
- Kamana Pillay
- Bo R. Rueda
- Daniel William Cramer
- Michael V. Seiden
- Michael J. Birrer
- George Coukos
- Lin Zhang
- John Quackenbush
- Dimitrios Spentzos
References
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
- Adjusting batch effects in microarray expression data using empirical Bayes methods
- Identifying biological themes within lists of genes with EASE
- Cancer of the Ovary
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
- Oncogenic pathway signatures in human cancers as a guide to targeted therapies
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome